Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
Commentary|Videos|March 10, 2026
Dr Pearson on Using AI for Clinical Trial Design and Accrual
Author(s)Alexander T. Pearson, MD, PhD
Fact checked by: Kyle Doherty
Alexander T. Pearson, MD, PhD, discusses the role of AI for clinical trial design and enrollment.
Advertisement
Alexander T. Pearson, MD, PhD, explains how AI can be used to reduce the time needed to match suitable patients with cancer to clinical trials. AI models are able to synthesize information for nearly every available study in a disease setting, even those that may not be apparent to the treating oncologist. This enables a broad trial portfolio to be made available to the most appropriate patients, he concludes.
Advertisement
Related to this article
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
Roswell Park Comprehensive Cancer Center received a grant to advance CAR T-cell therapy research in pediatric AML.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
Safusidenib produced a 51.9% confirmed ORR and a 79.1% 36-month PFS rate in chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5